Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBridge Biosciences (NBP) Current Leases (2019 - 2025)

NovaBridge Biosciences (NBP) has 7 years of Current Leases data on record, last reported at $891000.0 in Q4 2025.

  • On a quarterly basis, Current Leases rose 9.19% to $891000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $891000.0, a 9.19% increase, with the full-year FY2025 number at $891000.0, up 9.19% from a year prior.
  • Current Leases reached $891000.0 in Q4 2025 per NBP's latest filing, up from $872000.0 in the prior quarter.
  • Over the last five years, Current Leases for NBP hit a ceiling of $4.8 billion in Q4 2021 and a floor of $737000.0 in Q2 2024.
  • A 5-year average of $370.8 million and a median of $891000.0 in 2025 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: soared 394417.06% in 2021, then plummeted 99.93% in 2022.
  • Tracing NBP's Current Leases over 5 years: stood at $4.8 billion in 2021, then tumbled by 99.93% to $3.4 million in 2022, then fell by 9.76% to $3.0 million in 2023, then crashed by 73.16% to $816000.0 in 2024, then grew by 9.19% to $891000.0 in 2025.
  • Business Quant data shows Current Leases for NBP at $891000.0 in Q4 2025, $872000.0 in Q3 2025, and $853000.0 in Q2 2025.